Consistent with our observation, it has been reported that compared to other hematologic malignancies, BFL1 levels are increased in DLBCL, and DLBCL lines that had increased BFL1 levels were more resistant to venetoclax [70]. This evidence concerns the gene BCL2A1 and diffuse large B-cell lymphoma.